SA
GILD icon

Seneschal Advisors’s Gilead Sciences GILD Stock Holding History

Seneschal Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52K Sell
12
-98
-89% -$12.9K ﹤0.01% 217
2026
Q1 		$15.3K Hold
110
– – 0.01% 129
2025
Q4 		$13.5K Hold
110
– – 0.01% 137
2025
Q3 		$12.2K Buy
+110
New +$12.5K 0.01% 141

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Seneschal Advisors's GILD Position: Q2 2026 in Review

Seneschal Advisors reduced its Gilead Sciences (GILD) stake by 89% in Q2 2026, selling an estimated $12.9K and leaving 12 shares worth $1.52K. The position accounts for ﹤0.01% of the portfolio, ranked #217.

Seneschal Advisors first reported a position in GILD in Q3 2025 and has held it in 4 quarters since. The position peaked at $15.3K in Q1 2026. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Seneschal Advisors held 12 shares of Gilead Sciences worth $1.52K as of Q2 2026.
  • Seneschal Advisors sold 98 Gilead Sciences shares in Q2 2026, an estimated $12.9K.
  • Gilead Sciences made up ﹤0.01% of Seneschal Advisors's portfolio in Q2 2026, its #217 holding.
  • Seneschal Advisors first reported a position in Gilead Sciences in Q3 2025 and has held it in 4 quarters since.
  • Seneschal Advisors's Gilead Sciences position peaked at $15.3K in Q1 2026.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Seneschal Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.